StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Tuesday morning. The firm issued a sell rating on the stock.

Oragenics Price Performance

Shares of OGEN stock opened at $1.13 on Tuesday. The business’s fifty day simple moving average is $1.93. The company has a market capitalization of $5.06 million, a PE ratio of -0.12 and a beta of 0.31. Oragenics has a 52 week low of $1.02 and a 52 week high of $7.74.

Oragenics (NYSE:OGEN) last released its earnings results on Friday, March 29th. The company reported ($5.48) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in shares of Oragenics by 24.4% during the 4th quarter. Renaissance Technologies LLC now owns 288,398 shares of the company’s stock worth $30,000 after acquiring an additional 56,498 shares during the period. Millennium Management LLC raised its holdings in Oragenics by 591.6% in the 2nd quarter. Millennium Management LLC now owns 128,733 shares of the company’s stock valued at $45,000 after acquiring an additional 110,119 shares in the last quarter. Finally, State Street Corp raised its holdings in Oragenics by 8.1% in the 1st quarter. State Street Corp now owns 495,563 shares of the company’s stock valued at $171,000 after acquiring an additional 37,338 shares in the last quarter. 18.71% of the stock is currently owned by institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.